HEADER HYDROLASE/HYDROLASE INHIBITOR 07-FEB-13 4J54 TITLE CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL TITLE 2 ISOLATE PR20 WITH THE POTENT ANTIVIRAL INHIBITOR GRL-0519A COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 501-599; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_COMMON: HIV-1; SOURCE 4 ORGANISM_TAXID: 11676; SOURCE 5 GENE: POL; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET11A KEYWDS MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20, CLINICAL KEYWDS 2 INHIBITOR AMPRENAVIR, POTENT ANTIVIRAL INHIBITOR GRL-0519A, POTENT KEYWDS 3 ANTIVIRAL INHIBITOR GRL-02031, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR Y.-F.WANG,J.AGNISWAMY,I.T.WEBER REVDAT 3 20-SEP-23 4J54 1 REMARK SEQADV REVDAT 2 05-JUN-13 4J54 1 JRNL REVDAT 1 15-MAY-13 4J54 0 JRNL AUTH J.AGNISWAMY,C.H.SHEN,Y.F.WANG,A.K.GHOSH,K.V.RAO,C.X.XU, JRNL AUTH 2 J.M.SAYER,J.M.LOUIS,I.T.WEBER JRNL TITL EXTREME MULTIDRUG RESISTANT HIV-1 PROTEASE WITH 20 MUTATIONS JRNL TITL 2 IS RESISTANT TO NOVEL PROTEASE INHIBITORS WITH JRNL TITL 3 P1'-PYRROLIDINONE OR P2-TRIS-TETRAHYDROFURAN. JRNL REF J.MED.CHEM. V. 56 4017 2013 JRNL REFN ISSN 0022-2623 JRNL PMID 23590295 JRNL DOI 10.1021/JM400231V REMARK 2 REMARK 2 RESOLUTION. 1.55 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.55 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 92.4 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.203 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.200 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.260 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1212 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 24122 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.187 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.184 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.244 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 1055 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 20648 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1518 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 75 REMARK 3 SOLVENT ATOMS : 88 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1653.6 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 0.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 3 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 6784 REMARK 3 NUMBER OF RESTRAINTS : 6513 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 ANGLE DISTANCES (A) : 0.025 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.032 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.043 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.053 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.019 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.000 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.073 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER, J.MOL.BIOL.91(1973)201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4J54 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 13-FEB-13. REMARK 100 THE DEPOSITION ID IS D_1000077607. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 04-AUG-10 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8 REMARK 200 MONOCHROMATOR : ROSENBAUM-ROCK DOUBLE-CRYSTAL REMARK 200 SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24299 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.550 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 92.5 REMARK 200 DATA REDUNDANCY : 6.100 REMARK 200 R MERGE (I) : 0.06900 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 22.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.55 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.61 REMARK 200 COMPLETENESS FOR SHELL (%) : 50.2 REMARK 200 DATA REDUNDANCY IN SHELL : 1.80 REMARK 200 R MERGE FOR SHELL (I) : 0.26500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASES REMARK 200 STARTING MODEL: PDB ENTRY 2HS2 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 39.28 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.03 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.25 M POTASSIUM IODIDE, 0.1 M SODIUM REMARK 280 ACETATE, PH 4.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 14.28600 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 46.41050 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 32.89400 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 46.41050 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 14.28600 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 32.89400 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 7180 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 10050 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -32.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 35 38.16 -157.79 REMARK 500 ALA B 67 -113.65 47.74 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ILE B 66 ALA B 67 -140.77 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 G52 B 101 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE G52 A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 203 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 204 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 205 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 206 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 207 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 208 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 209 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 210 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 211 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 212 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 214 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 215 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT A 216 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE G52 B 101 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 102 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 103 REMARK 800 REMARK 800 SITE_IDENTIFIER: CC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 106 REMARK 800 REMARK 800 SITE_IDENTIFIER: CC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 107 REMARK 800 REMARK 800 SITE_IDENTIFIER: CC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 108 REMARK 800 REMARK 800 SITE_IDENTIFIER: CC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 109 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3UCB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH DARUNAVIR REMARK 900 RELATED ID: 3UFN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH SAQUINAVIR REMARK 900 RELATED ID: 3UF3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH YTTRIUM(III) CHLORIDE REMARK 900 RELATED ID: 3UHL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH THE P2-NC SUBSTRATE ANALOG REMARK 900 RELATED ID: 3OK9 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH THE POTENT REMARK 900 ANTIVIRAL INHIBITOR GRL-0519A REMARK 900 RELATED ID: 4J55 RELATED DB: PDB REMARK 900 RELATED ID: 4J5J RELATED DB: PDB DBREF 4J54 A 1 99 UNP P03367 POL_HV1BR 501 599 DBREF 4J54 B 1 99 UNP P03367 POL_HV1BR 501 599 SEQADV 4J54 LYS A 7 UNP P03367 GLN 507 ENGINEERED MUTATION SEQADV 4J54 PHE A 10 UNP P03367 LEU 510 ENGINEERED MUTATION SEQADV 4J54 VAL A 13 UNP P03367 ILE 513 ENGINEERED MUTATION SEQADV 4J54 VAL A 15 UNP P03367 ILE 515 ENGINEERED MUTATION SEQADV 4J54 ASN A 30 UNP P03367 ASP 530 ENGINEERED MUTATION SEQADV 4J54 ILE A 32 UNP P03367 VAL 532 ENGINEERED MUTATION SEQADV 4J54 PHE A 33 UNP P03367 LEU 533 ENGINEERED MUTATION SEQADV 4J54 ASP A 35 UNP P03367 GLU 535 ENGINEERED MUTATION SEQADV 4J54 ILE A 36 UNP P03367 MET 536 ENGINEERED MUTATION SEQADV 4J54 ASN A 37 UNP P03367 SER 537 ENGINEERED MUTATION SEQADV 4J54 VAL A 47 UNP P03367 ILE 547 ENGINEERED MUTATION SEQADV 4J54 LEU A 54 UNP P03367 ILE 554 ENGINEERED MUTATION SEQADV 4J54 GLU A 58 UNP P03367 GLN 558 ENGINEERED MUTATION SEQADV 4J54 VAL A 62 UNP P03367 ILE 562 ENGINEERED MUTATION SEQADV 4J54 PRO A 63 UNP P03367 LEU 563 ENGINEERED MUTATION SEQADV 4J54 ALA A 67 UNP P03367 CYS 567 ENGINEERED MUTATION SEQADV 4J54 VAL A 71 UNP P03367 ALA 571 ENGINEERED MUTATION SEQADV 4J54 VAL A 84 UNP P03367 ILE 584 ENGINEERED MUTATION SEQADV 4J54 ASP A 88 UNP P03367 ASN 588 ENGINEERED MUTATION SEQADV 4J54 THR A 89 UNP P03367 LEU 589 ENGINEERED MUTATION SEQADV 4J54 MET A 90 UNP P03367 LEU 590 ENGINEERED MUTATION SEQADV 4J54 ALA A 95 UNP P03367 CYS 595 ENGINEERED MUTATION SEQADV 4J54 LYS B 7 UNP P03367 GLN 507 ENGINEERED MUTATION SEQADV 4J54 PHE B 10 UNP P03367 LEU 510 ENGINEERED MUTATION SEQADV 4J54 VAL B 13 UNP P03367 ILE 513 ENGINEERED MUTATION SEQADV 4J54 VAL B 15 UNP P03367 ILE 515 ENGINEERED MUTATION SEQADV 4J54 ASN B 30 UNP P03367 ASP 530 ENGINEERED MUTATION SEQADV 4J54 ILE B 32 UNP P03367 VAL 532 ENGINEERED MUTATION SEQADV 4J54 PHE B 33 UNP P03367 LEU 533 ENGINEERED MUTATION SEQADV 4J54 ASP B 35 UNP P03367 GLU 535 ENGINEERED MUTATION SEQADV 4J54 ILE B 36 UNP P03367 MET 536 ENGINEERED MUTATION SEQADV 4J54 ASN B 37 UNP P03367 SER 537 ENGINEERED MUTATION SEQADV 4J54 VAL B 47 UNP P03367 ILE 547 ENGINEERED MUTATION SEQADV 4J54 LEU B 54 UNP P03367 ILE 554 ENGINEERED MUTATION SEQADV 4J54 GLU B 58 UNP P03367 GLN 558 ENGINEERED MUTATION SEQADV 4J54 VAL B 62 UNP P03367 ILE 562 ENGINEERED MUTATION SEQADV 4J54 PRO B 63 UNP P03367 LEU 563 ENGINEERED MUTATION SEQADV 4J54 ALA B 67 UNP P03367 CYS 567 ENGINEERED MUTATION SEQADV 4J54 VAL B 71 UNP P03367 ALA 571 ENGINEERED MUTATION SEQADV 4J54 VAL B 84 UNP P03367 ILE 584 ENGINEERED MUTATION SEQADV 4J54 ASP B 88 UNP P03367 ASN 588 ENGINEERED MUTATION SEQADV 4J54 THR B 89 UNP P03367 LEU 589 ENGINEERED MUTATION SEQADV 4J54 MET B 90 UNP P03367 LEU 590 ENGINEERED MUTATION SEQADV 4J54 ALA B 95 UNP P03367 CYS 595 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO PHE VAL THR VAL SEQRES 2 A 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASN THR ILE PHE GLU ASP ILE ASN LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET VAL GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE LEU LYS VAL ARG GLU TYR ASP GLN VAL PRO ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN VAL ILE GLY ARG ASP THR MET THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO PHE VAL THR VAL SEQRES 2 B 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASN THR ILE PHE GLU ASP ILE ASN LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET VAL GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE LEU LYS VAL ARG GLU TYR ASP GLN VAL PRO ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN VAL ILE GLY ARG ASP THR MET THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET G52 A 201 42 HET IOD A 202 1 HET IOD A 203 1 HET IOD A 204 1 HET IOD A 205 1 HET IOD A 206 1 HET IOD A 207 1 HET IOD A 208 1 HET IOD A 209 1 HET IOD A 210 1 HET IOD A 211 1 HET IOD A 212 1 HET IOD A 213 1 HET IOD A 214 1 HET IOD A 215 1 HET ACT A 216 4 HET G52 B 101 7 HET IOD B 102 1 HET IOD B 103 1 HET IOD B 104 1 HET IOD B 105 1 HET IOD B 106 1 HET IOD B 107 1 HET IOD B 108 1 HET IOD B 109 1 HETNAM G52 (3R,3AS,3BR,6AS,7AS)-OCTAHYDRODIFURO[2,3-B:3',2'- HETNAM 2 G52 D]FURAN-3-YL [(1S,2R)-1-BENZYL-2-HYDROXY-3-{[(4- HETNAM 3 G52 METHOXYPHENYL)SULFONYL](2-METHYLPROPYL) HETNAM 4 G52 AMINO}PROPYL]CARBAMATE HETNAM IOD IODIDE ION HETNAM ACT ACETATE ION FORMUL 3 G52 2(C30 H40 N2 O9 S) FORMUL 4 IOD 22(I 1-) FORMUL 18 ACT C2 H3 O2 1- FORMUL 28 HOH *88(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLN A 92 GLY A 94 5 3 HELIX 3 3 GLY B 86 GLN B 92 1 7 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N THR A 96 O ASN B 98 SHEET 4 A 4 GLN B 2 ILE B 3 -1 O ILE B 3 N LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O GLU A 58 N LYS A 43 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O VAL A 71 N ILE A 64 SHEET 4 B 8 ILE A 32 PHE A 33 1 N PHE A 33 O LEU A 76 SHEET 5 B 8 VAL A 84 ILE A 85 -1 O VAL A 84 N ILE A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 PHE A 10 VAL A 15 -1 N VAL A 13 O LYS A 20 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 LYS B 43 GLY B 49 0 SHEET 2 C 8 GLY B 52 ILE B 66 -1 O GLU B 58 N LYS B 43 SHEET 3 C 8 HIS B 69 VAL B 77 -1 O VAL B 71 N ILE B 64 SHEET 4 C 8 ILE B 32 PHE B 33 1 N PHE B 33 O LEU B 76 SHEET 5 C 8 VAL B 84 ILE B 85 -1 O VAL B 84 N ILE B 32 SHEET 6 C 8 GLN B 18 LEU B 24 1 N LEU B 23 O ILE B 85 SHEET 7 C 8 PHE B 10 VAL B 15 -1 N VAL B 13 O LYS B 20 SHEET 8 C 8 GLY B 52 ILE B 66 -1 O GLU B 65 N LYS B 14 SITE 1 AC1 19 ASP A 25 GLY A 27 ALA A 28 ASP A 29 SITE 2 AC1 19 ASN A 30 GLY A 48 ILE A 50 VAL A 82 SITE 3 AC1 19 ASP B 25 GLY B 27 ALA B 28 ASP B 29 SITE 4 AC1 19 ASN B 30 ILE B 32 GLY B 48 GLY B 49 SITE 5 AC1 19 ILE B 50 VAL B 82 HOH B1001 SITE 1 AC2 2 ASP A 35 ASN A 83 SITE 1 AC3 1 G52 B 101 SITE 1 AC4 1 ACT A 216 SITE 1 AC5 2 THR A 12 IOD A 206 SITE 1 AC6 1 IOD A 205 SITE 1 AC7 2 GLU A 21 ASN A 83 SITE 1 AC8 4 GLU A 21 VAL A 82 HOH A 340 ARG B 8 SITE 1 AC9 1 GLU A 65 SITE 1 BC1 1 THR A 4 SITE 1 BC2 1 ARG B 8 SITE 1 BC3 5 LYS A 14 GLY A 16 GLY A 17 PRO A 63 SITE 2 BC3 5 HOH A 344 SITE 1 BC4 2 PRO A 44 HOH A 338 SITE 1 BC5 2 GLN A 61 HOH A 341 SITE 1 BC6 3 PHE A 53 ARG A 57 IOD A 204 SITE 1 BC7 5 IOD A 203 VAL B 56 THR B 91 GLY B 94 SITE 2 BC7 5 HOH B1024 SITE 1 BC8 2 ASP B 35 GLY B 78 SITE 1 BC9 1 GLU B 21 SITE 1 CC1 1 ALA B 67 SITE 1 CC2 3 THR B 12 HOH B1041 HOH B1042 SITE 1 CC3 1 MET B 46 SITE 1 CC4 2 PRO B 39 GLY B 40 CRYST1 28.572 65.788 92.821 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.034999 0.000000 0.000000 0.00000 SCALE2 0.000000 0.015200 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010773 0.00000